ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01607658
Recruitment Status : Completed
First Posted : May 30, 2012
Results First Posted : August 13, 2018
Last Update Posted : August 13, 2018
Sponsor:
Information provided by (Responsible Party):
Acerus Pharmaceuticals Corporation

Brief Summary:
The purpose of this study is to assess and compare the effects of 3 dose strengths of TBS-2 intranasal testosterone gel to placebo on the occurrence of orgasm.

Condition or disease Intervention/treatment Phase
Female Orgasmic Disorder Drug: Placebo Drug: Low dose TBS-2 Drug: Medium dose TBS-2 Drug: High dose TBS-2 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 253 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder
Study Start Date : May 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
Drug: Placebo
placebo intranasal gel administered prn, 2-8 hours before a planned sexual event

Experimental: Experimental 1
Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
Drug: Low dose TBS-2
Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event

Experimental: Experimental 2
Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
Drug: Medium dose TBS-2
Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event

Experimental: Experimental 3
High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
Drug: High dose TBS-2
High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event




Primary Outcome Measures :
  1. Number of Orgasms Over an 84 Day Period Compared to Placebo Over the Entire Treatment Period [ Time Frame: 84 days ]

Secondary Outcome Measures :
  1. Change in Sexual Event Satisfaction Over a 28-day Period (Day 57 to Day 84) Compared to Baseline (Day -28 to Day 0) [ Time Frame: Baseline (Day -28 to Day 0) and End of Study (Day 57 to 84) ]

    as measured by Monash Women's Health Program Female Sexual Satisfaction Questionnaire (MONASH WHP FSSQ) question 11.

    MONASH WHP FSSQ question 11 asks participants to comment on how satisfying they found the sex to be from "Not at all" to "Very much so". The lowest score is 1 and the highest is 9. All scores for each 28-day period were averaged. Change from baseline was obtained by subtracting baseline 28-day average from the 28-day period at the end of the study (Day 57 to 84).


  2. Change in Distress Due to Female Orgasmic Disorder From Day 0 Baseline to Day 84 [ Time Frame: Day 0 and Day 84 ]
    as measured by Female Sexual Distress Scale (FSDS-DAO) Question #15 on Day 0 and 84, respectively. Question #15 evaluates the level of distress related to problems with orgasm. It is rated on a 5-point Likert scale (from 0 to 4, i.e. never [0], rarely [1], occasionally [2], frequently [3], or always [4]). Higher scores indicate more distress.

  3. Change in Global Sexual Functioning From Day 0 to Day 84 [ Time Frame: Day 0 and Day 84 ]
    as measured by Female Sexual Function Index (FSFI) on Day 0 and 84, respectively. The FSFI, a 19-item questionnaire, has been developed as a brief, multidimensional self-report instrument for assessing the key dimensions of sexual frustration in women. The questionnaire provides scores on 6 domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) as well as a total score. Fifteen items are rated on a 6-point Likert scale (from 0 to 5) and 4 items on a 5-point Likert scale (from 1 to 5). The scores are added and converted using a conversion factor so that the maximum score for each domain is 6. The overall FSFI score can range from 2 to 36. Higher scores indicate better or higher sexual function.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subjects who meet the following criteria may be included in the study:

At Visit 1:≤

  • Be a generally healthy female aged 18 years and older, inclusive, who has no physical impediment to sexual function
  • Have a diagnosis of acquired female orgasmic disorder defined as absence of orgasm during the past 6 months and according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria. Subtype should be generalized and not due to etiological factors that would be unlikely to be related to hormone function (eg, depression, relationship discord, alcoholism, surgery, injury). Hypoactive sexual desire disorder as a co-morbid disorder is allowed only if it began after the female orgasmic disorder diagnosis;
  • Have a score of >15 with a score of ≥2 for question #15 on the FSDS DAO at Screening Visit;
  • Be a sexually active, hetero- or homosexual woman in a steady relationship for at least 6 months and agree to have at least 4 sexual events over 28-day period of time. The subject's partner should not have any untreated sexual dysfunctions;
  • Be on a reliable birth control method (ie, stable systemic hormonal contraception for the whole duration of the study and 30 days after study completion [for at least 3 months prior to study], IUD, barrier method) or not engaging in heterosexual intercourse. Birth control method used by subject at screening is not to be changed during the course of the study;
  • Have a normal ENT examination;
  • Have a body mass index ≤35;
  • Have a clinically acceptable pelvic examination and Pap smear as read by a licensed laboratory facility (no evidence of malignancy) within the 2 years prior to Randomization;
  • Have a clinically acceptable mammogram;
  • Be able to complete a web-based questionnaire within 24 hours of each sexual event;
  • Be able to read English and provide written informed consent; and

At Visit 2:

  • Have at least 4 sexual events and an absence of orgasm during the 28 day Screening/Baseline Period as determined by MONASH WHP FSSQ.

Exclusion Criteria

Subjects who meet any of the following criteria will not be eligible to participate in the study:

  • Have a known history of hypersensitivity to testosterone or any component of the study drug;
  • Have a history of any clinically relevant psychiatric disorder that could impact sexual functioning, contribute to increased risk for patient safety, or significantly compromise participation in the study (eg, bipolar disorders, psychotic disorders, severe anxiety, eating disorders, borderline personality disorder, untreated Major Depressive Disorder);
  • Have a score of ≥14 on the Beck Depression Inventory II at Screening Visit. Subjects with a score of ≥14 and ≤19 at Screening may be eligible to participate in the study if a specialist (psychologist or psychiatrist) concludes that the subject is not clinically depressed;
  • Have other concurrent female sexual dysfunction disorders as defined by DSM-IV criteria, eg, Sexual Aversion Disorder, Substance-Induced sexual dysfunction, dyspareunia (not caused by inadequate foreplay stimulation or alleviated by lubricants), vaginismus, Gender Identity Disorder, paraphilia, or sexual dysfunction due to a general medical condition;
  • Be experiencing relational discord;
  • Have a history of dementia or other neurodegenerative diseases, organic brain disease, stroke, transient ischemic attacks, brain surgery, significant brain trauma, multiple sclerosis, spinal cord injury, peripheral neuropathy, and epilepsy (febrile seizures limited to childhood do not exclude patients);
  • Be currently receiving treatment with selective norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) and/or medications that interfere with the metabolism of testosterone (eg, anastrozole, clomiphene, testolactone, ketoconazole, spironolactone, histamine 2 [H2 receptor blockers, etc.]);
  • Have a history of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or be a regular drinker of more than 3 units of alcohol daily (1 unit = 300 mL beer, 1 glass wine, 1 measure spirit);
  • Have a history of cancer other than nonmelanotic skin cancer;
  • Have a history of deep venous thrombosis or coagulation disorders;
  • Have a significant medical condition (eg, hepatic, renal cardiovascular, endocrine including diabetes mellitus). Subjects with treated hypertension, treated hyperlipidemia, or treated thyroid disease will not be excluded provided they have been on stable therapy for at least 3 months;
  • Had any major surgical procedure within the past 6 months including hysterectomy, hysterectomy with bilateral salpingo oophorectomy, or vaginal incontinence surgery
  • Are receiving treatment with systemic glucocorticosteroids, sex steroid hormones such as androgens (eg, dehydroepiandrosterone [DHEA]) or gestagens (eg, anabolic steroids) and using any post menopausal hormone therapy;
  • Have a history of severe or multiple drug allergies, severe adverse drug reaction or drug-related leucopenia;
  • Have a history of nasal disorders (eg, atrophic rhinitis, polyposis, abuse of nasal decongestants, clinically relevant nasal septum deviation, recurrent epistaxis), sinus disease or nasal surgery and/or seasonal or perennial allergic rhinitis in the active phase;
  • Be using any form of chronic intranasal medication delivery, specifically nasal corticosteroids or decongestants;
  • Have a diagnosis of sleep apnea and be using a continuous positive airway pressure/automatic positive airway device;
  • Have a history of diagnosed hirsutism, alopecia or clinically significant acne;
  • Have a history of diagnosed polycystic ovarian syndrome;
  • Have pelvic inflammatory disease, chronic urinary tract, vaginal, or cervical infections, interstitial cystitis, vulvodynia, or significant symptomatic vaginal atrophy;
  • Are currently pregnant, by history or positive serum pregnancy test at Screening Visit or have been pregnant within the 12 months prior to Screening Visit;
  • Is breast feeding or have breast fed within the 6 months prior to Screening Visit;
  • Are positive for hepatitis B-surface antigen, hepatitis C, or Human Immunodeficiency Virus (HIV);
  • Have abnormal thyroid stimulating hormone level;
  • For pre-menopausal women, have SHBG value <18 86 nmol/L; For post-menopausal women, have SHBG value >160 nmol/L
  • Have any medical or psychiatric condition, physical examination finding, or laboratory result which, in the opinion of the principal investigator, would put the subject at additional medical risk or make her unlikely to be able to comply with study requirements; or
  • Have received any drug as part of a research study within 30 days prior to the Screening Visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01607658


  Show 53 Study Locations
Sponsors and Collaborators
Acerus Pharmaceuticals Corporation
Investigators
Study Director: Natalia Tkachenko, MD Trimel Pharmaceuticals Corporation

Responsible Party: Acerus Pharmaceuticals Corporation
ClinicalTrials.gov Identifier: NCT01607658     History of Changes
Other Study ID Numbers: TBS-2-AMB-2012-01
First Posted: May 30, 2012    Key Record Dates
Results First Posted: August 13, 2018
Last Update Posted: August 13, 2018
Last Verified: August 2018

Keywords provided by Acerus Pharmaceuticals Corporation:
Testosterone

Additional relevant MeSH terms:
Disease
Sexual Dysfunctions, Psychological
Pathologic Processes
Mental Disorders
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents